olivLaw · US equity research
Quantum-Si Incorporated QSI
Measuring & Controlling Devices, NEC · SIC 3829 · Vertical: Measuring & Controlling Devices, NEC (SIC 3829)
Quantum-Si is a proteomics technology company developing single-molecule protein sequencing, with its Platinum and Platinum Pro instruments already on the market. The company is in a transition period: revenue is very small and the Proteus platform launch has been pushed to Q2 2027, making the runway of available capital a central issue.
At the close of 04 Nov 2026, Quantum-Si Incorporated (QSI) stock was 1.29 USD (−0.77% on the day), with beta 2.42, 52-week range 0.70–1.80 USD. Latest reported quarter (Q2 2026): revenue of 344.0 k USD (−41.8% YoY), net income of -23.5 m USD, diluted EPS -0.11 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 50.0
- neutral
- Bollinger (20, 2)
- 0.99 – 1.73
- in the lower half of the band · %B 0.40 · band width 54.6%
- SMA 50 / 200
- 1.07 / 0.97
- uptrend (price > SMA50 > SMA200)
- MACD (12, 26, 9)
- 0.09 / 0.12
- MACD below signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +0.8% | −1.1% | +1.9 pp | — |
| 3 months | +70.4% | −0.5% | +70.9 pp | — |
| 6 months | +25.2% | +4.4% | +20.9 pp | — |
| Year to date | +17.3% | +12.3% | +5.0 pp | — |
| 1 year | −29.9% | +13.5% | −43.4 pp | −33.4% |
| 3 years | −5.8% | +76.4% | −82.3 pp | +16.9% |
| 5 years | −83.7% | +63.7% | −147.3 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 787.0 k | 1.2 m | 842.0 k | 591.0 k | 552.0 k | 451.0 k | 258.0 k | 344.0 k |
| Cost of revenue | 420.0 k | 582.0 k | 356.0 k | 240.0 k | 358.0 k | 329.0 k | 184.0 k | 172.0 k |
| Gross profit | 367.0 k | 610.0 k | 486.0 k | 351.0 k | 194.0 k | 122.0 k | 74.0 k | 172.0 k |
| Research & development | 16.2 m | 17.0 m | 13.7 m | 15.2 m | 13.9 m | 10.9 m | 14.5 m | 15.8 m |
| SG&A | 12.3 m | 14.3 m | 11.9 m | 11.9 m | 10.7 m | 10.3 m | 9.6 m | 10.0 m |
| Operating income | -28.1 m | -30.7 m | -25.1 m | -30.1 m | -39.8 m | -21.1 m | -24.1 m | -25.6 m |
| Depreciation & amortisation | 1.2 m | 994.0 k | 917.0 k | 1.2 m | 1.2 m | 1.2 m | 1.2 m | 1.2 m |
| Pre-tax income | -25.3 m | -33.1 m | -19.2 m | -28.8 m | -35.7 m | -17.6 m | -21.8 m | -23.5 m |
| Income tax | 43.0 k | 13.0 k | 11.0 k | 20.0 k | 19.0 k | 8.0 k | -122.0 k | 0 |
| Net income | -25.3 m | -33.1 m | -19.2 m | -28.8 m | -35.7 m | -17.6 m | -21.7 m | -23.5 m |
| Diluted EPS | -0.18 | -0.23 ≈ | -0.11 | -0.16 | -0.17 | -0.08 ≈ | -0.10 | -0.11 |
| Operating cash flow | -23.2 m ≈ | -22.9 m | -26.2 m | -20.2 m ≈ | -32.0 m ≈ | -16.3 m | -25.6 m | -18.4 m ≈ |
| Capex | 975.0 k ≈ | 1.4 m | 1.3 m | 327.0 k ≈ | 900.0 k ≈ | -17.0 k | 279.0 k | 78.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | unavailable | unavailable | 0 | 0 | 1.1 m | 3.1 m | 2.4 m |
| Revenue YoY | unavailable | unavailable | unavailable | unavailable | unavailable | +182.6% | −20.3% |
| Net income | -35.8 m | -36.6 m | -95.0 m | -132.4 m | -96.0 m | -101.0 m | -101.3 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -6.95 | -6.84 | -1.19 | -0.95 | -0.68 | -0.71 | -0.51 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | unavailable | unavailable | unavailable | unavailable | -8,868.8% | -3,303.0% | -4,160.1% |
| Free cash flow | -31.9 m | -33.0 m | -72.6 m | -101.3 m | -98.5 m | -92.4 m | -97.2 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 21.6 m USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 220.2 m USD
- Total assets
- 245.6 m USD
- Debt / equity
- unavailable
- Current ratio
- 7.64x
- ROE
- -46.5%
- ROA
- -41.1%
- FCF margin
- -3,991.5%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 1.1 m | 3.1 m | 2.4 m | SEC (XBRL)· 03 Mar 2026verified |
| Cost of revenue | — | 0 | 0 | 594.0 k | 1.5 m | 1.3 m | SEC (XBRL)· 03 Mar 2026verified |
| Gross profit | — | 0 | 0 | 488.0 k | 1.6 m | 1.2 m | SEC (XBRL)· 03 Mar 2026verified |
| Research & development | 27.6 m | 46.6 m | 72.1 m | 67.0 m | 59.6 m | 53.8 m | SEC (XBRL)· 03 Mar 2026verified |
| SG&A | 9.1 m | 50.3 m | 42.3 m | 44.6 m | 50.5 m | 44.8 m | SEC (XBRL)· 03 Mar 2026verified |
| Operating income | -36.7 m | -96.9 m | -123.8 m | -111.2 m | -108.6 m | -116.1 m | SEC (XBRL)· 03 Mar 2026verified |
| Depreciation & amortisation | 894.0 k | 1.0 m | 2.6 m | 4.2 m | 4.6 m | 4.5 m | SEC (XBRL)· 03 Mar 2026verified |
| EBITDA | -35.8 m ≈ | -95.9 m ≈ | -121.3 m ≈ | -107.0 m ≈ | -104.0 m ≈ | -111.6 m ≈ | SEC (XBRL)· 03 Mar 2026derived |
| Interest expense | 9.0 k | 5.0 k | 0 | — | — | — | SEC (XBRL)· 17 Mar 2023verified |
| Pre-tax income | -36.6 m | -95.0 m | -132.4 m | -96.0 m | -101.0 m | -101.3 m | SEC (XBRL)· 03 Mar 2026verified |
| Income tax | 0 | 0 | 0 | 0 | 56.0 k | 58.0 k | SEC (XBRL)· 03 Mar 2026verified |
| Net income | -36.6 m | -95.0 m | -132.4 m | -96.0 m | -101.0 m | -101.3 m | SEC (XBRL)· 03 Mar 2026verified |
| Diluted EPS | -6.84 | -1.19 | -0.95 | -0.68 | -0.71 | -0.51 | SEC (XBRL)· 03 Mar 2026verified |
| Weighted average diluted shares | 5.4 m | 79.6 m | 139.3 m | 141.3 m | 143.2 m | 197.8 m | SEC (XBRL)· 03 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 36.9 m | 35.8 m | 84.3 m | 133.9 m | 49.2 m | 21.6 m | SEC (XBRL)· 03 Mar 2026verified |
| Receivables | — | — | 0 | 368.0 k | 1.3 m | 561.0 k | SEC (XBRL)· 03 Mar 2026verified |
| Inventories | — | — | 0 | 3.9 m | 4.1 m | 3.2 m | SEC (XBRL)· 03 Mar 2026verified |
| Current assets | 37.9 m | 477.2 m | 358.2 m | 266.3 m | 218.0 m | 175.9 m | SEC (XBRL)· 03 Mar 2026verified |
| Property, plant & equipment, net | 2.0 m | 8.9 m | 16.8 m | 16.3 m | 16.0 m | 13.2 m | SEC (XBRL)· 03 Mar 2026verified |
| Goodwill | 0 | 9.5 m | 0 | — | — | — | SEC (XBRL)· 17 Mar 2023verified |
| Intangibles (excl. goodwill) | — | — | 0 | 532.0 k | 0 | — | SEC (XBRL)· 03 Mar 2025verified |
| Total assets | 40.6 m | 503.2 m | 391.5 m | 298.3 m | 247.9 m | 245.6 m | SEC (XBRL)· 03 Mar 2026verified |
| Accounts payable | 1.3 m | 3.4 m | 3.9 m | 1.8 m | 1.9 m | 1.6 m | SEC (XBRL)· 03 Mar 2026verified |
| Current liabilities | 2.8 m | 11.5 m | 15.7 m | 11.6 m | 18.2 m | 23.0 m | SEC (XBRL)· 03 Mar 2026verified |
| Total liabilities | 4.5 m | 26.2 m | 32.8 m | 26.6 m | 32.5 m | 25.4 m | SEC (XBRL)· 03 Mar 2026verified |
| Equity | -159.7 m † | 477.0 m † | 358.7 m † | 271.6 m † | 215.4 m † | 220.2 m † | SEC (XBRL)· 03 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -32.6 m | -66.8 m | -90.6 m | -94.0 m | -87.8 m | -94.7 m | SEC (XBRL)· 03 Mar 2026verified |
| Capex | 461.0 k | 5.8 m | 10.7 m | 4.5 m | 4.6 m | 2.5 m | SEC (XBRL)· 03 Mar 2026verified |
| Free cash flow | -33.0 m ≈ | -72.6 m ≈ | -101.3 m ≈ | -98.5 m ≈ | -92.4 m ≈ | -97.2 m ≈ | SEC (XBRL)· 03 Mar 2026derived |
| Investing cash flow | -461.0 k | -450.9 m | 137.2 m | 143.4 m | -32.7 m | -28.3 m | SEC (XBRL)· 03 Mar 2026verified |
| Financing cash flow | 37.0 m | 516.6 m | 1.9 m | 149.0 k | 35.9 m | 95.4 m | SEC (XBRL)· 03 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 2 of at least 6
- score weight coverage: 10.4% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: unavailable
Key indicators
Coverage and freshness
Score by group
10% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the reported interest expense is far older than the latest period (the filer changed its XBRL tag): a stale figure is not used
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 2 of at least 6; score weight coverage: 10.4% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -6,138.3% | 0 (vs peers) | 60% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | unavailable | unavailable | — |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | unavailable | unavailable | — |
| Current ratio · Balance sheet | 10.0x | 100 (on a fixed band) | 40% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | unavailable | unavailable | — |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet· partial100/100 · 1/3 factors with a value
- Growth· partialunavailable · 0/2 factors with a value
- Quality· partial0/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partialunavailable · 0/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
QUANTUM-SI INCORPORATED (QSI). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 2.4 m USD in 2025; YoY growth -20.3%; net margin -6,138.3%; ROE -49.1%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 2 of at least 6; score weight coverage: 10.4% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Current ratio: 10.0x
What contradicts it
- Net margin: -6,138.3%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, Revenue CAGR 3Y, EPS CAGR 3Y, Net debt / EBITDA, Interest coverage, P/E (TTM), EV/EBITDA, FCF yield, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Measuring & Controlling Devices, NEC (SIC 3829) · same industry (4-digit SIC) · compared with 9 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| TMOThermo Fisher Scientific Inc. | 261.6 bn | 37.3 | 13.4% | 14.9% | +3.9% | +20% / +42% |
| ROKRockwell Automation, Inc. | 49.3 bn | 41.6 | 34.5% | 13.4% | +0.9% | +12% / +61% |
| TRMBTrimble Inc. | 12.4 bn | — | -2.9% | -4.1% | −2.6% | −33% / +17% |
| ONTOOnto Innovation Inc. | 9.1 bn | 69.4 | 6.8% | 11.8% | unavailable | +29% / +31% |
| MIRMirion Technologies, Inc. | 336.9 m | 159.4 | 1.6% | 2.7% | +7.5% | −31% / +101% |
| OWLTOwlet, Inc. | 132.4 m | — | — | -7.7% | +35.4% | −66% / −10% |
| GEOSGeospace Technologies Corp | 51.0 m | — | -34.4% | -43.1% | −18.3% | −70% / −67% |
| BCHTBirchtech Corp. | 28.9 m | — | -134.4% | -21.7% | +1.3% | −75% / −78% |
| NIKINiki BioSolutions, Inc. | — | — | -6.2% | — | −66.7% | −87% / −90% |
| QSIQuantum-Si Incorporated | — | — | -49.1% | -6,138.3% | −20.3% | −30% / −6% |
1- and 3-year price returns: for QSI from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Quantum-Si is a proteomics technology company developing single-molecule protein sequencing, with its Platinum and Platinum Pro instruments already on the market. The company is in a transition period: revenue is very small and the Proteus platform launch has been pushed to Q2 2027, making the runway of available capital a central issue 123.
SWOT
Strengths
- By its own account the company was the first to commercialise a next-generation protein sequencing product, and its instruments carry a far lower acquisition cost than mass spectrometry 1.
- The management team has experience launching successful sequencing technologies at other companies, which may help execution 1.
- The company has kept a relatively solid liquidity position, with funds that could support operations for some time if the plan is followed 23.
Weaknesses
- Revenue is very small and fell in 2026, and the company has persistent net losses and a large accumulated deficit 123.
- The main new product depends on a platform whose launch has already been delayed, which weighs on market credibility 12.
- The company has carried out several staff reductions and cost cuts, which points to pressure on its expense structure 13.
Opportunities
- Non-human markets such as agriculture and pathogen detection could significantly widen the customer base if products meet their requirements 3.
- If Proteus reaches the announced performance, the company could displace more expensive instruments in core laboratories and in countries with limited access 1.
- Recurring consumable sales could provide steadier revenue once the installed base grows 1.
Threats
Risks
- Delay of the Proteus launchhigh
If Proteus is not launched within the communicated timeframe or without the promised applications, the impact on growth and credibility could be significant 12.
- Need for additional capitalhigh
The company could need new funds sooner than planned, and issuing new shares could dilute existing shareholders 13.
- Customers postponing purchasesmedium
Customers could delay buying instruments and consumables until Proteus is launched, reducing revenue during the transition 12.
- Limited adoption of the new technologymedium
If laboratories do not adopt the technology at scale, consumable revenue could remain small 1.
- Tariffs and supply chainlow
Tariffs or supply chain disruptions could affect component costs and product availability 1.
Investment thesis
What would need to be true (bull case)
- If Proteus launches in Q2 2027 with the promised performance, the company could open larger markets in both human and non-human research 13.
- If the cost reduction takes hold, liquidity could support operations through the stated period, giving time for execution 3.
- If the installed base of instruments grows, recurring consumable sales could produce more stable revenue 1.
What would break the thesis
- If the Proteus launch is delayed again, very low revenue and persistent losses could put pressure on financing and on the company's credibility 123.
- If customers keep postponing purchases, transition-period revenue could stay close to zero for longer 2.
- If new share issues are needed, existing shareholders' stake could be diluted 1.
What to watch
- Commercial launch of Proteus and first shipmentsQ2 2027
- Development of consumable and instrument revenueQ4 2026
- Realisation of the cost savings announced after the workforce reduction2027
- Annual report on revenue and losses and update of financial guidancenext 10-K
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Quantum-Si Incorporated is a life sciences company focused on proteomics research, aiming to make single-molecule protein analysis broadly accessible. Its platform includes the Platinum and Platinum Pro instruments, library preparation and sequencing consumable kits, and analysis software, all intended for research use only (RUO) 1. The company says a lower instrument price than mass spectrometry could broaden adoption in smaller research labs 1. Consumable sales are described as the expected source of recurring revenue 1.
The company launched Platinum fully commercially in Q2 2024 and Platinum Pro in March 2025 1. Revenue remained very low: in the first half of 2026 it was 602 thousand dollars, against 1.4 million dollars a year earlier, as customers transition toward Proteus 23. The company describes 2026 as a transition year 3.
The Proteus platform, announced in November 2024, is designed as a modular system with higher output and greater automation, and is intended to displace some equipment in core laboratories 1. Its launch was rescheduled first to the second half of 2026 and then to Q2 2027, to add an integrated instrument design cycle 23.
Segments
Market context
The company estimates the total proteomics opportunity at 75 billion dollars including diagnostics, and the research proteomics market at 20 billion dollars, of which it initially targets about 8 billion dollars 1. More recently it estimated an opportunity of more than 4 billion dollars a year in non-human markets such as agriculture and pathogen detection 3.
The market is fragmented, with legacy technologies such as mass spectrometry and affinity methods, and adoption is largely confined to core laboratories 1. In many countries access to advanced tools is very limited, which could favour a lower-cost product 1.
Trends
- Transition to Proteusheadwind
Customers could postpone instrument and consumable purchases until Proteus is launched, which affects near-term revenue 12.
- Demand for proteomicstailwind
Growing interest in protein analysis for biology and diagnostics could support long-term demand, if the new instruments meet expectations 1.
- Macroeconomic conditionsmixed
Interest rates, inflation and supply chain disruptions are monitored by the company and could affect laboratory budgets and production costs 1.
- Trade tariffsheadwind
Tariffs have not so far materially affected the company, but its finished goods or components could be affected if tariffs increase 1.
Competitive position
The main competitors are established technologies, notably mass spectrometry, along with affinity-based methods and Edman degradation sequencing 1. The company argues it can play a complementary role in core laboratories and, with Proteus, replace specialised instruments 1.
- Mass spectrometry instrument makers
The dominant technology for unbiased protein analysis, with high acquisition and running costs but a large installed base in core laboratories 1.
- Affinity-based methods
Use antibodies or aptamers, are effective for known proteins, and are cited by the company as limited in detecting protein variants 1.
- Edman degradation sequencing
An older method offering amino acid level resolution, but it is labour-intensive, uses hazardous chemicals and has limited use 1.
- Core proteomics laboratories
Not direct product competitors, but they are the current channel for complex proteomics work and a possible replacement target for Proteus 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report15 Oct 2026Other events · Financial statements and exhibits
- Current report08 Oct 2026Regulation FD disclosure · Financial statements and exhibits
- Current report29 Sept 2026Regulation FD disclosure · Financial statements and exhibits
- Quarterly report13 Aug 2026
- Current report13 Aug 2026Results of operations · Financial statements and exhibits
- Current report24 Jul 2026Delisting notice
- Current report24 Jun 2026Material agreement · Creation of a direct financial obligation · Financial statements and exhibits
- Current report15 May 2026Shareholder vote
- Quarterly report07 May 2026
- Current report07 May 2026Results of operations · Financial statements and exhibits
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Quantum-Si Incorporated · 03 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Quantum-Si Incorporated · 13 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Quantum-Si Incorporated · 13 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.